How can pharmaceutical companies anticipate and address payer resistance to expensive, but cost-effective new therapies?

In this article, Andrew Butcher writes about the importance of stakeholder engagement as effective but high-cost new therapies have potentially damaging financial implications for the healthcare systems expected to fund them. Regrettably, the pharmaceutical industry is often identified as the cause of the problems rather than the key players in solving them.